Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 12:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 38 matching trials from the live ClinicalTrials.gov search.
Conditions
Progressive Supranuclear Palsy, Corticobasal Syndrome
Interventions
Fasudil
Drug
Lead sponsor
Woolsey Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Recruiting No phase listed Observational Accepts healthy volunteers

The CurePSP Genetics Program

NCT06647641
Conditions
PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration Syndrome, Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), MSA, MSA - Multiple System Atrophy, MSA-C, Multiple System Atrophy, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Parkinsonian Type, Progressive Supranuclear Palsy, Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP)
Interventions
Whole genome sequencing will be performed at the NIH
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT02966145
Conditions
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 4 more
Recruiting No phase listed Observational Accepts healthy volunteers

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684
Conditions
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Completed No phase listed Observational Accepts healthy volunteers

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02365922
Conditions
FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), PPA Syndrome, Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis (ALS), Oligosymptomatic PSP (oPSP), Corticobasal Syndrome (CBS)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
1,489 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Studies in Corticobasal Syndrome

NCT07000851
Conditions
Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Interventions
C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
Diagnostic Test
Lead sponsor
Jennifer Whitwell
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Alzheimer's Disease, Fronto-temporal Dementia, Parkinson Disease (PD), Cortico Basal Degeneration, Posterior Cortical Atrophy (PCA), Neurological Diseases or Conditions
Interventions
MemorEM
Device
Lead sponsor
NeuroEM Therapeutics, Inc.
Industry
Eligibility
45 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Completed Not applicable Interventional

Vaccination Uptake (VAX) in PD

NCT02874274
Conditions
Parkinson's Disease
Interventions
Standard of Care, Home Visit Program (HVP)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Conditions
Corticobasal Degeneration, Corticobasal Syndrome, Pain, Neuropathic
Interventions
Scrambler therapy, TENS treatment
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland